	Jun 2025	Mar 2025	Jun 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	537.55	496.63	395.87	8.2%	35.8%
Operating Profit Qtr	81.11	86.37	38.08	-6.1%	113.0%
Net Profit Qtr	55.83	58.25	-11.79	-4.2%	573.5%
Earning Per Share Adjusted latest Qtr	22.33	23.30	-4.72	-4.2%	573.1%

* Standalone data

Detailed Results

AstraZeneca Pharma India Ltd.

12 Aug 2025

8460.50

1.58%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Please find the enclosed intimation of the Company as per the captioned subject for reference.

pdf

AstraZeneca Pharma India Ltd.

06 Aug 2025

8460.50

1.58%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Launch Of Eculizumab (Soliris)

BSE India

Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.

pdf

AstraZeneca Pharma India Ltd.

01 Aug 2025

8460.50

1.58%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Clarification On News Item Appearing In Https://Www.Moneycontrol.Com

BSE India

Please find the enclosed letter of the Company in relation to the captioned subject for your reference.

pdf

AstraZeneca Pharma India Ltd.

01 Aug 2025

8460.50

1.58%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Clarification sought from AstraZeneca Pharma India Ltd

BSE India

The Exchange has sought clarification from AstraZeneca Pharma India Ltd on August 1, 2025, with reference to news appeared in https://www.moneycontrol.com dated August 1, 2025 quoting "Trump Tariff News Live: GSK and AstraZeneca among top companies told to ''cut US prices or else".The reply is awaited.

Is AstraZeneca Pharma India Ltd. worth buying?

148 Votes:

Buy 70.95%

Sell 19.59%

Hold 9.46%